GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Gross-Profit-to-Asset %

Curocell (XKRX:372320) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Curocell Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Curocell's annualized Gross Profit for the quarter that ended in Jun. 2023 was ₩0.00 Mil. Curocell's average Total Assets over the quarter that ended in Jun. 2023 was ₩88,190.31 Mil. Therefore, Curocell's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 0.00%.


Curocell Gross-Profit-to-Asset % Historical Data

The historical data trend for Curocell's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Gross-Profit-to-Asset % Chart

Curocell Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
- 0.06 - - -

Curocell Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % - - - -

Competitive Comparison of Curocell's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Curocell's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curocell's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curocell's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Curocell's Gross-Profit-to-Asset % falls into.



Curocell Gross-Profit-to-Asset % Calculation

Curocell's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (87987.733+104969.386)/ 2 )
=0/96478.5595
=0.00 %

Curocell's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=0/( (87987.733+88392.885)/ 2 )
=0/88190.309
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Curocell Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Curocell's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Curocell (XKRX:372320) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell (XKRX:372320) Headlines

No Headlines